Epidemiological evidence consistently demonstrates an inverse relationship between circulating adiponectin levels and the risk of obesity-related cancers, including endometrial, breast, advanced prostate, colorectal, and renal cancers [103,105]. Here, ADIPOQ is linked to obesity disorder.